ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibition, Macrophage Checkpoint Inhibition, TP53 Modulators

27 views
March 8, 2021
Comments 0
Login to view comments. Click here to Login